Bivalent Poliomyelitis Vaccine type 1 & 3, Live (Oral)
For children and adults
BIOPOLIO® B1/3

DESCRIPTION
The live Bivalent Oral Polio type 1 & type 3 Vaccine (bOPV 1 & 3) contains suspension of live attenuated polioviruses type 1 and type 3 viruses (Sabin strain) prepared in Primary Monkey Kidney Cells. Each dose contains not less than 10^6 CCID50 virus concentration of type 1 strain and 10^5 CCID50 virus concentration of type 3 strain. bOPV 1 & 3 contains magnesium chloride (MgCl2) 1Molar as stabilizer, and kanamycin and neomycin sulphate as antibiotics. The vaccine fulfills WHO requirements for Bivalent Poliomyelitis Vaccine type 1 & 3, Live (oral).

ADMINISTRATION
BIOPOLIO B1/3 must only be administered orally. Two drops are delivered directly into the mouth of the vaccinee from the multi dose vial by dropper or dispenser. Care should be taken not to contaminate the multi dose dropper with saliva of the vaccinee.

Multi-dose vials of bOPV 1 & 3 from which one or more doses of vaccine have been removed during an immunization session may be used in subsequent immunization sessions for up to a maximum of 28 days after opening, provided that all of the following conditions are met (as described in the WHO Policy Statement: Multi-dose Vial Policy (MDVP) Revision 2014 WHO/IWG/14.07).

• The vaccine is currently prequalified by WHO.
• The vaccine is approved for use for up to 28 days after opening of the vial, as determined by WHO (http://www.who.int/immunization_standards/vaccine_quality/PQ_vaccine_list/en/).
• The expiry date of the vaccine has not passed.
• The vaccine vial has been, and will continue to be, stored at the recommended temperature; furthermore, the vaccine vial monitor is visible on the vaccine label and is not past its discard point, and the vaccine has not been damaged by freezing.

IMMUNIZATION SCHEDULE
Bivalent Oral Polio type 1 & type 3 vaccine is indicated for routine immunization against polioviruses in children from 0 to 5 years of age, to interrupt transmission of type 1 & type 3 polioviruses. It is also indicated for polioviruses Supplementary Immunization Activities (SIAs) in all age groups, to interrupt type 1 & type 3 polioviruses transmission in the remaining polio endemic areas.

bOPV type 1 & 3 can be administered safely and effectively at the same time as measles, rubella, mumps, inactivated polio vaccine (IPV), DPT, DT, TT, BCG, Haemophilus influenzae type b, yellow fever and hepatitis B vaccines and Vitamin A supplement.

SIDE EFFECTS
In the vast majority of cases there are no side effects reported with the trivalent OPV that includes the same bOPV 1 & 3 components. Very rarely, there may be vaccine-associated paralytic poliomyelitis.

CONTRAINDICATIONS
No adverse effects are produced by giving bOPV type 1 & 3 to a sick child. In case of diarrhea, the dose received will not be counted as part of the immunization schedule and it should be repeated after recovery.

IMMUNE DEFICIENCY
Individuals infected with human immunodeficiency virus (HIV), both asymptomatic and symptomatic, should be immunized with bOPV 1 & 3 according to standard schedules. However, the vaccine is contraindicated in those with primary immune deficiency disease or suppressed immune response from medication, leukemia, lymphoma or generalized malignancy.

STORAGE
The recommended storage temperature for Bivalent Oral Poliomyelitis Vaccine (bOPV) is at -20°C or below until the expiry date indicated on the vial. It can be stored for up to six months between +2°C and +8°C.

PRESENTATION
Bivalent Oral Polio type 1 & type 3 vaccine is presented as 10 doses per vial and 20 doses per vial.

Vaccine Vial Monitors (VVMs) are part of the label on all bOPV 1 & 3 vials. VVMs are supplied by TEMPTIME Corporation, U.S.A. The colour dot which appears on the label of the vial is a VVM. This is a time-temperature sensitive dot that provides an indication of the cumulative heat to which the vial has been exposed. It warns the end user when exposure to heat is likely to have degraded the vaccine beyond an acceptable level.

The interpretation of the VVM is simple: Focus on the central square; its colour will change progressively. As long as the colour of this square is lighter than the colour of the ring, the vaccine can be used. As soon as the colour of the central square is the same colour as the ring or of a darker colour than the ring, the vial should be discarded.

Manufactured & Marketed by:
Bharat Biotech International Ltd., Genome Valley, Shamshabad Mandal, Range Reddy District - 500 078
Telangana, India.
email: feedback@bharatbiotech.com
www.bharatbiotech.com

Date: 05-11-2015
BIOPOLIO® B1/3 Pack Insert WHO Export & Domestic
Colors CMYK/Pantone
Specs
Product
Size
Strength
Paper
GSM
Print
Folds
90x200 mm
10 & 20 dose
Maplitho
80±10
Front & Back
V-3
90x25

Approval QA - RA
Corp comm
Packing
Incharge
HOD - QC
Incharge-IPQA
Marketing (Domestic / Export)
MDA
HOD - QAO

Signatures

Form No: FMQA/008/004.02 The coral version of this form can be with corpcom.